Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Siltuximab for Myelofibrosis
NCT02805868Phase 1Withdrawn
- Sponsor
- Northwestern University
- Start
- Jun 2016
- Primary completion
- Feb 2019
- Modality
- Monoclonal Antibodies
01
Overview
Phase 1, open-label, single-arm trial of siltuximab in myelofibrosis (MF), sponsored by Northwestern University. Primary endpoint: Incidence of Adverse Events. Planned start Jun 2016; status: withdrawn.
02
Drugs
siltuximab
03
Conditions
myelofibrosis (MF)
Beyond the preview
Go deeper on NCT02805868.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02805868.